Biomarkers in the management of heart failure

被引：12

作者：

Kim H.-N. ^{[1
]}

Januzzi Jr. J.L. ^{[1
]}

机构：

[1] Cardiology Division, Massachusetts General Hospital, Boston, MA 02114, 32 Fruit Street

来源：

Current Treatment Options in Cardiovascular Medicine | 2010年 / 12卷 / 6期

关键词：

Heart Failure; Natriuretic Peptide; Heart Failure Patient; Systolic Heart Failure; Heart Failure Therapy;

D O I：

10.1007/s11936-010-0096-3

中图分类号：

学科分类号：

摘要：

Opinion statement: Biomarkers, especially natriuretic peptides such as B-type natriuretic peptide (BNP) and N-terminal-proBNP (NT-proBNP), are a valuable addition to standard clinical assessment in the diagnosis and prognosis of heart failure (HF). Furthermore, there is an increasing amount of evidence suggesting that natriuretic peptide-guided HF management may improve mortality, morbidity, and cost effectiveness. This work focuses on the use of BNP or NT-proBNP for the outpatient management of patients with chronic HF. © 2010 Springer Science+Business Media, LLC.

引用

页码：519 / 531

页数：12

共 47 条

[1]

Singh V., Martinezclark P., Pascual M., Et al., Cardiac biomarkers-the old and the new: A review, Coron Artery Dis, 21, pp. 244-256, (2010)

[2]

Braunwald E., Medical progress: Biomarkers in heart failure, New England Journal of Medicine, 358, 20, (2008)

[3]

Mann D.L., Pathophysiology of heart failure, Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 8, (2007)

[4]

Piao F.L., Park S.H., Han J.H., Cao C., Kim S.Z., Kim S.H., Dendroaspis natriuretic peptide and its functions in pig ovarian granulosa cells, Regulatory Peptides, 118, 3, pp. 193-198, (2004)

[5]

Omland T., Hagve T.A., Natriuretic peptides: Physiologic and analytic considerations, Heart Fail Clin, 5, pp. 471-487, (2009)

[6]

Rubattu S., Sciarretta S., Morriello A., Et al., NPR-C: A component of the natriuretic peptide family with implications in human diseases, J Mol Med, (2010)

[7]

Richards M., Troughton R.W., NT-proBNP in heart failure: Therapy decisions and monitoring, European Journal of Heart Failure, 6, 3, pp. 351-354, (2004)

[8]

Van Kimmenade R.R., Januzzi Jr. J.L., Bakker J.A., Et al., Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects, J Am Coll Cardiol, 53, pp. 884-890, (2009)

[9]

Maisel A.S., Krishnaswamy P., Nowak R.M., McCord J., Hollander J.E., Duc P., Omland T., Storrow A.B., Abraham W.T., Wu A.H.B., Clopton P., Steg P.G., Westheim A., Knudsen C.W., Perez A., Kazanegra R., Herrmann H.C., McCullough P.A., Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure, New England Journal of Medicine, 347, 3, pp. 161-167, (2002)

[10]

Januzzi Jr. J.L., Camargo C.A., Anwaruddin S., Baggish A.L., Chen A.A., Krauser D.G., Tung R., Cameron R., Nagurney J.T., Chae C.U., Lloyd-Jones D.M., Brown D.F., Foran-Melanson S., Sluss P.M., Lee-Lewandrowski E., Lewandrowski K.B., The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study, American Journal of Cardiology, 95, 8, pp. 948-954, (2005)

← 1 2 3 4 5 →